Anonymous ID: e7dbd2 July 24, 2020, 10:22 a.m. No.10065530   🗄️.is 🔗kun   >>5612 >>5622 >>5735

Wind the clock metaphor decoded

Seems that clock fags have gotten the times wrong

DROPS 1-60 WERE THE CRUMBS

They were the minutes in a timestamp that gave context to drops 60

 

https://threadreaderapp.com/thread/1286655204302127105.html

 

Attached as PDF for those who want it for offline study.

Anonymous ID: e7dbd2 July 24, 2020, 10:27 a.m. No.10065553   🗄️.is 🔗kun

We know that Coronavirus kills by clogging up the lungs. So why don't people just cough up the fluid? Because it is too thick and gooey!!! So why not use a mucolytic to thin the mucus. Will that help patients cough it all up and survive? Bromhexine is a mucolytic

Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection

 

https://pubmed.ncbi.nlm.nih.gov/32334052/

 

Dear Editor,

 

Bromhexine is an over-the-counter mucolytic cough suppressant that was introduced in 1963 under the trademark of Bisolvon®. It is a widely prescribed drug for treatment of a range of respiratory conditions, mainly those associated with a disturbance of mucus secretion, and it is well tolerated and safe. Chemical library screening for discovery of suppressors of prostate cancer metastasis identified bromhexine as a potent and selective inhibitor of the TMPRSS2 (Transmembrane Protein Serine 2) protease displaying an IC50 of 0.75 μM [1]. This is important since TMPRSS2 is an androgen regulated cell-surface serine protease that belongs to the very few trypsin-like proteases expressed in the human respiratory tract. It plays a role in the proteolytic activation and invasion of the human airway epithelium by influenza [2] as well as SARS-CoV and MERS [3] viruses.

 

The spread of the COVID-19 coronavirus pandemic is a major crisis of public health and has stimulated intensive efforts to find treatments active against the SARS-CoV-2 virus. Hoffmann et al. [4] proposed the TMPRSS2 serine protease inhibitor camostat mesylate [5], a drug approved in Japan for use in chronic pancreatitis, for off-label treatment of SARS-CoV-2-infected patients. Their proposal is grounded in the finding that SARS-CoV-2 cell entry depends on binding of the viral spike (S) protein to cellular angiotensin converting enzyme 2 receptor and priming of the S protein by host cell TMPRSS2 protease [4]. Hoffmann’s study indicated that cleavage of the viral S protein by TMPRSS2 protease occurs at S1/S2 arginine rich multibasic site: this is prevented by camostat mesylate which accordingly inhibits the entry of SARS-CoV-2 virus into Calu-3 lung cell lines and primary human airway epithelial cells. Furthermore, based on studies of influenza and other coronaviruses, TMPRSS2 may also regulate viral assembly in the Golgi apparatus and release of SARS-CoV-2-from the plasma membrane as previously suggested by Shen et al. [6].

 

The interaction of bromhexine with the TMPRSS2 enzyme together with its widespread clinical use and safety strongly support its evaluation in patients with SARS-CoV-2 infection, especially since the use of camostat mesylate is much less well established and very expensive. Indeed, bromhexine was already proposed by Shen et al. [6] as a candidate drug for treatment of SARS-CoV and MERS virus infections. Furthermore, pharmacokinetic data support the testing of bromhexine use for this indication since, in pulmonary and bronchial epithelial cells, it may reach concentrations 4 to 6-fold higher than those found in the plasma, high enough in principle to inhibit TMPRSS2 (bromhexine datasheet: https://www.medsafe.govt.nz/Profs/Datasheet/b/BisolvonTabSol.pdf).

 

Bromhexine hydrochloride is already in the pipeline for COVID-19 treatment, as a mucolytic medication for chest congestion and cough in patients with suspected and mild novel coronavirus pneumonia in China (ClinicalTrials.gov Identifier: NCT04273763). Recognition of the inhibitory effects of bromhexine at TMPRSS2 suggest its repurposing either as a treatment for patients with full-blown COVID-19 infections, or as a prophylactic agent to prevent the infection of high-risk subjects with SARC-CoV-2, which would also impede spreading of the virus. These observations warrant rigorous clinical trials of bromhexine, either alone or in association with other antivirals agents.

 

We thank Dr. Mark J. Millan for helpful discussions and comments on the letter.

 

Go to the PMC Full Text reference on Pubmed and you will also see the 6 papers referenced as sources for this letter. It has already been cited by the authors of other research papers as well.

Anonymous ID: e7dbd2 July 24, 2020, 10:44 a.m. No.10065709   🗄️.is 🔗kun

>>10065626

Yesterday Trump showed a chart with COVID cases increasing in Houston and South Florida

But look at this chart on the seasonality of respiratory disease from the attached video.

The North Tropical zone would normally be experiencing an increase in cases in July August timeframe

This seems to explain Trump's chart.

Anonymous ID: e7dbd2 July 24, 2020, 11:09 a.m. No.10065951   🗄️.is 🔗kun

Barrack Obama was the richest ever US President

His adopted father, Lolo Soetoro was one of the 10-15 richest people in the world

And he left a trust fund to his adopted son Barry Soetoro when he died.

 

Maybe we have not dug deeply enough into Lolo Soetoro and his connections

Was he involved in the Communist takeover of China, for instance?